Sawai Group Holdings Co Ltd
TSE:4887

Watchlist Manager
Sawai Group Holdings Co Ltd Logo
Sawai Group Holdings Co Ltd
TSE:4887
Watchlist
Price: 2 362 JPY -2.17% Market Closed
Market Cap: ¥272.7B

Relative Value

The Relative Value of one Sawai Group Holdings Co Ltd stock under the Base Case scenario is 2 277.53 JPY. Compared to the current market price of 2 362 JPY, Sawai Group Holdings Co Ltd is Overvalued by 4%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
2 277.53 JPY
Overvaluation 4%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Sawai Group Holdings Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Sawai Group Holdings Co Ltd
TSE:4887
272.8B JPY 1.4 -250.2 18.7 370
US
Eli Lilly and Co
NYSE:LLY
954.4B USD 16.1 51.8 34.8 37.3
US
Johnson & Johnson
NYSE:JNJ
547B USD 5.8 20.4 14.2 17.4
CH
Roche Holding AG
SIX:ROG
268.4B CHF 4.4 28.6 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP 4.9 30.3 19.7 28.9
CH
Novartis AG
SIX:NOVN
219B CHF 5 19.3 15.5 20
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.4 13.2
US
Merck & Co Inc
NYSE:MRK
265.9B USD 4.1 13.9 9.9 11.7
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
147.8B USD 2.3 15 7.6 10.4
FR
Sanofi SA
PAR:SAN
94.4B EUR 1.4 6.9 6.3 6.3
P/E Multiple
Earnings Growth PEG
JP
Sawai Group Holdings Co Ltd
TSE:4887
Average P/E: 22.5
Negative Multiple: -250.2
23%
N/A
US
Eli Lilly and Co
NYSE:LLY
51.8
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.4
6%
3.4
CH
Roche Holding AG
SIX:ROG
28.6
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.3
38%
0.8
CH
Novartis AG
SIX:NOVN
19.3
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
2%
8.2
US
Merck & Co Inc
NYSE:MRK
13.9
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
27%
0.6
FR
Sanofi SA
PAR:SAN
6.9
25%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
Sawai Group Holdings Co Ltd
TSE:4887
Average EV/EBITDA: 45
18.7
11%
1.7
US
Eli Lilly and Co
NYSE:LLY
34.8
34%
1
US
Johnson & Johnson
NYSE:JNJ
14.2
2%
7.1
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
19.7
10%
2
CH
Novartis AG
SIX:NOVN
15.5
6%
2.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
6.3
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
Sawai Group Holdings Co Ltd
TSE:4887
Average EV/EBIT: 126.8
370
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.3
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.4
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
28.9
23%
1.3
CH
Novartis AG
SIX:NOVN
20
12%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5
FR
Sanofi SA
PAR:SAN
6.3
15%
0.4